Sensitive and Repeatable Analysis of InstantPC-labeled N-Glycans from Human Immunoglobulin G

Significance of the topic

Glycosylation of therapeutic proteins—particularly monoclonal antibodies and Fc-fusion biologics—is a critical quality attribute because it strongly influences stability, solubility, immunogenicity, pharmacokinetics, and effector functions. Reliable analytical workflows able to detect and quantify both abundant and low‑level N-glycoforms are therefore essential for process development, comparability, release testing, and regulatory decision making. High-sensitivity, high-resolution UHPLC separations combined with robust fluorescence detection improve confidence in glycan profiling and reduce the need for repeat analyses.

Objectives and overview of the study

This application note evaluates the performance of the Agilent 1290 Infinity III Bio LC System with the Agilent 1290 Infinity III Fluorescence Detector (FLD) for rapid, sensitive, and repeatable analysis of InstantPC (IPC)‑labeled N‑glycans released from human immunoglobulin G (HuIgG). The goals were to demonstrate UHPLC peak fidelity (minimal dispersion), low limits of detection and quantification (LOD, LOQ), excellent run‑to‑run precision, and a wide linear dynamic range suitable for both high‑ and low‑abundance glycoforms.

Methods and used instrumentation

• System: Agilent 1290 Infinity III Bio LC System configured with High-Speed Pump, Multisampler, Multicolumn Thermostat (with Quick Connect Bio Heat Exchanger) and Agilent 1290 Infinity III FLD using a 2 µL FLD flow cell.
• Software: Agilent OpenLab CDS v2.8 or later.
• Column: Agilent AdvanceBio Amide HILIC, RRHD, 2.1 × 150 mm, 1.8 µm.
• Mobile phases: A = 50 mM ammonium formate, pH 4.4; B = acetonitrile. Gradient: 25% A → 37% A at 20 min → 60% A at 27 min; total run 30 min with 10 min post time.
• Chromatographic parameters: flow 0.700 mL/min; column temperature 60 °C; injection volume 1 µL; sample temp 10 °C.
• Detection: FLD excitation 285 nm, emission 345 nm, standard PMT gain, peak width criterion >0.1 min (5 Hz).
• Standards and labeling: InstantPC HuIgG N‑glycan library and multiple IPC glycan standards (Man5, G0, G0F, G2F, G2FS2 etc.). Samples prepared by dissolving IPC‑labeled standards/library in mobile phase A and diluting to concentrations spanning 10 pmol/µL down to 0.16 fmol/µL.
• LOD/LOQ criteria: LOD set at S/N = 3; LOQ set at S/N = 10. Linearity and precision assessed using calibration series and repeated injections (n = 10).

Experimental details and sample preparation

The IPC HuIgG N‑glycan library was reconstituted in mobile phase A. For sensitivity and linearity studies, IPC‑labeled glycan standards (M5, A2, FA2, FA2G2, FA2G2S2) were combined at 200 pmol each and serially diluted to cover the range 10 pmol/µL down to 0.16 fmol/µL. Calibration curves were constructed across the working ranges to evaluate linearity, LOD and LOQ.

Results and discussion

Separation performance: The method resolved the predominant HuIgG N‑glycans (17 assigned peaks) within a 30‑minute UHPLC run. Neutral, non‑sialylated glycans elute before sialylated species. Peak assignments followed Oxford nomenclature and common biopharma mAb acronyms.

Run‑to‑run precision: Ten consecutive injections of the IPC HuIgG library produced excellent retention time repeatability (RT RSD ≤ 0.16% for all peaks) and peak area repeatability (area RSD ≤ 0.57% for all peaks). These low RSD values indicate high method robustness and minimal contribution from detector or system dispersion.

Sensitivity, linearity, LOD and LOQ: Calibration for five representative glycans showed strong linearity across the tested ranges with correlation coefficients (R²) > 0.999. Linearity was maintained from as low as 0.16 fmol/µL to 10 pmol/µL for several glycans; for larger structures (FA2G2 and FA2G2S2), linearity was demonstrated from 0.8 fmol/µL to 10 pmol/µL. Observed LODs ranged from approximately 0.07 to 0.32 fmol/µL and LOQs from ~0.23 to 1.05 fmol/µL depending on the glycan. These limits were determined using S/N thresholds of 3 (LOD) and 10 (LOQ).

Detector contribution: The 2 µL FLD flow cell provided high sensitivity and a broad linear dynamic range while contributing minimal dispersion—supporting UHPLC peak fidelity that preserves chromatographic resolution even for closely eluting glycoforms.

Key quantitative performance highlights

• Retention time RSD (n = 10): ≤ 0.16% across all 17 assigned HuIgG glycans.
• Peak area RSD (n = 10): ≤ 0.57% across all assigned glycans.
• Linearity: R² > 0.999 for representative glycans across tested ranges.
• LOD (S/N = 3): between ~0.07 and 0.32 fmol/µL depending on glycan.
• LOQ (S/N = 10): between ~0.23 and 1.05 fmol/µL depending on glycan.

Benefits and practical applications

The demonstrated workflow is suitable for routine glycan profiling in biopharmaceutical development and quality control. Benefits include:

• Confident detection and quantification of low‑abundance glycoforms (fmol/µL sensitivity), important for monitoring critical quality attributes and biosimilarity assessments.
• High chromatographic fidelity and low detector-induced dispersion, preserving resolution for complex glycan mixtures.
• Excellent precision and wide linear dynamic range, enabling accurate quantification across multiple orders of magnitude without frequent reruns.
• Reduced operational costs and higher throughput through fewer repeat analyses and robust performance.

Future trends and potential applications

As glycan analysis becomes increasingly integral to biopharma analytics, key future directions include:

• Integration of sensitive fluorescence detection with orthogonal mass spectrometry workflows for structural confirmation while retaining high‑throughput quantitative UHPLC screening.
• Further miniaturization and reduced dispersion FLD cell designs to push sensitivity and resolution for trace glycoforms.
• Expanded standardized libraries and automated data processing to streamline release testing, comparability studies, and biosimilar development.
• Application of high‑confidence glycan profiling in real‑time process analytics and PAT (process analytical technology) frameworks to enable tighter control of glycosylation during manufacturing.

Conclusion

The Agilent 1290 Infinity III Bio LC System with the 1290 Infinity III FLD and a 2 µL FLD cell achieves sensitive, repeatable, and high‑fidelity UHPLC separations of InstantPC‑labeled N‑glycans from HuIgG. The method delivers low LOD/LOQ in the sub‑fmol/µL range for many glycans, excellent linearity (R² > 0.999), and outstanding precision (RT and area RSDs well below 1%). These attributes support confident detection and quantification of low‑abundance glycoforms and make the platform well suited for biopharmaceutical glycan characterization and routine QC applications.

References

1. Zhang L.; Luo S.; Zhang B. Glycan Analysis of Therapeutic Glycoproteins. mAbs 2016, 8(2), 205–215.
2. Meudt M.; Baumeister J.; Mizaikoff B.; Ebert S.; Rosenau F.; Blech M.; Higel F. Comprehensive Analysis and Characterization of Glycan Pairing in Therapeutic Antibodies and Fc‑Containing Biotherapeutics. Eur J Pharm Biopharm 2024, 200, 114325.
3. Luo S.; Zhang B. Benchmark Glycan Profile of Therapeutic Monoclonal Antibodies Produced by Mammalian Cell Expression Systems. Pharm Res 2023, 41(1), 29–37.
4. Schneider S. Sensitive and Reproducible Glycan Analysis of Human Immunoglobulin G. Agilent Technologies application note, 2012.
5. Arnold et al. Human Immunoglobulin Glycosylation and the Lectin Pathway of Complement Activation. Adv Exp Med Biol 2005, 564, 27–43.
6. Fernandes D. Demonstrating Comparability of Antibody Glycosylation During Biomanufacturing. European Biopharmaceutical Review, Summer 2005, 106–110.
7. Melmer et al. HILIC Analysis of Fluorescence‑Labeled N‑glycans from Recombinant Biopharmaceuticals. Anal Bioanal Chem 2010, 398, 905–914.